share_log

Even Though MannKind (NASDAQ:MNKD) Has Lost US$66m Market Cap in Last 7 Days, Shareholders Are Still up 392% Over 5 Years

Even Though MannKind (NASDAQ:MNKD) Has Lost US$66m Market Cap in Last 7 Days, Shareholders Are Still up 392% Over 5 Years

儘管曼恩凱德生物醫療(納斯達克:MNKD)在過去7天內市值已經縮水了6600萬美元,但股東們在過去5年中仍然獲利392%。
Simply Wall St ·  10/24 21:07

For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly amazing gains over the years. Just think about the savvy investors who held MannKind Corporation (NASDAQ:MNKD) shares for the last five years, while they gained 392%. This just goes to show the value creation that some businesses can achieve. Also pleasing for shareholders was the 12% gain in the last three months. But this move may well have been assisted by the reasonably buoyant market (up 7.0% in 90 days).

對許多人來說,在股市投資的主要目的是實現驚人的回報。多年來,我們看到了一些真正驚人的收益。想想那些持有納斯達克(NASDAQ:MNKD)上市公司股票五年的明智投資者,他們的收益率爲392%。這只是一個例子,顯示了一些企業可以實現的價值創造。對股東們來說,過去三個月漲幅達到12%也讓人滿意。但這一舉動很可能受到市場相對樂觀的影響(在90天內上漲了7.0%)。

Although MannKind has shed US$66m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

儘管曼恩凱德生物醫療本週市值縮水了6600萬美元,讓我們來看看其更長期的基本趨勢,看看是什麼推動了回報。

While MannKind made a small profit, in the last year, we think that the market is probably more focussed on the top line growth at the moment. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.

雖然曼恩凱德生物醫療在過去一年中有微薄盈利,但我們認爲市場當前可能更關注其營業收入增長。一般來說,我們認爲這種公司更類似於虧損股票,因爲實際利潤非常低。股東們要想對一家公司增長利潤持有信心,它必須增加營業收入。

In the last 5 years MannKind saw its revenue grow at 32% per year. Even measured against other revenue-focussed companies, that's a good result. Arguably, this is well and truly reflected in the strong share price gain of 38%(per year) over the same period. It's never too late to start following a top notch stock like MannKind, since some long term winners go on winning for decades. On the face of it, this looks lke a good opportunity, although we note sentiment seems very positive already.

在過去的5年裏,曼恩凱德生物醫療的營業收入每年增長32%。即使與其他以營業收入爲重點的公司進行對比,也可以獲得不錯的結果。可以說,這已經清楚地反映在相同時期每年38%的強勁股價增長中。現在開始跟蹤曼恩凱德等一流股票永遠不算晚,因爲一些長期贏家會持續幾十年贏下去。從表面上看,這似乎是一個好機會,儘管我們注意到市場情緒已經非常積極。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下面的圖表顯示了收益和營收隨時間的變化情況(通過單擊圖像揭示確切的值)。

big
NasdaqGM:MNKD Earnings and Revenue Growth October 24th 2024
納斯達克納斯達克GM:MNKD收益和營業收入增長2024年10月24日

It is of course excellent to see how MannKind has grown profits over the years, but the future is more important for shareholders. Take a more thorough look at MannKind's financial health with this free report on its balance sheet.

看到曼恩凱德生物醫療多年來的利潤增長當然是好事,但未來對於股東來說更重要。通過免費報告查看曼恩凱德生物醫療資產負債表,更全面地了解其財務健康狀況。

A Different Perspective

不同的觀點

We're pleased to report that MannKind shareholders have received a total shareholder return of 60% over one year. That's better than the annualised return of 38% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 5 warning signs we've spotted with MannKind (including 2 which are potentially serious) .

我們很高興地報告,曼恩凱德生物醫療股東在一年內獲得了總股東回報率高達60%。這比過去五年平均回報率38%要好,這意味着公司最近的表現更出色。持樂觀態度的人可能會將最近的TSR改善視爲表明業務本身隨着時間變得更好。我覺得長期觀察股價作爲業績代理很有趣。但爲了真正獲得洞察力,我們還需要考慮其他信息。因此,您應該了解我們在曼恩凱德生物醫療發現的5個警示信號(其中包括兩個可能較爲嚴重的)。

Of course MannKind may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,曼恩凱德生物醫療可能不是最好的股票選擇。因此,您可能希望查看這些免費的成長股集合。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論